LXRX — LEXICON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1062822 ·
Last close
$2.55
Market Cap
$1.13B
52W High
$2.55
52W Low
$1.49
ADV30
3,474,040
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 21,102,000 | 20,994,000 | -996,000 | -1,043,000 | 268,819,000 | 38,089,000 | 65,963,000 |
| Dec 2025 | 5,493,000 | 5,292,000 | -14,780,000 | -15,530,000 | 184,987,000 | 34,326,000 | 77,449,000 |
| Sep 2025 | 14,182,000 | 14,172,000 | -12,187,000 | -12,769,000 | 205,927,000 | 49,656,000 | 85,768,000 |
| Jun 2025 | 28,866,000 | 28,833,000 | 3,736,000 | 3,252,000 | 225,583,000 | 21,364,000 | 96,143,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-67,851,000
Investing CF
$113,020,000
Financing CF
$-48,499,000
CapEx
$-781,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,017,583,000
Inventory
$281,000
Receivables
$2,384,000
ST Investments
$61,904,000
EBIT TTM
$-42,003,000
Pretax Income TTM
$-50,342,000
Interest Exp TTM
$8,339,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$69,643,000
EBITDA
$-23,673,000
Free Cash Flow
$-28,858,250
Enterprise Value
$1,019,753,792
Total Cash
$170,658,000
Total Debt
$57,707,000
Shares Out
444,196,390
Trailing EPS
$-0.07
Book Value
$0.48
ROE
-16.0%
ROA
-5.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 49,803,000 | -48,911,000 | -50,341,000 | 184,987,000 | 77,449,000 | — | -67,851,000 |
| Dec 2024 | 31,081,000 | -197,117,000 | -200,403,000 | 298,420,000 | 152,470,000 | — | -178,780,000 |
| Dec 2023 | 1,204,000 | -171,750,000 | -177,119,000 | 229,429,000 | 136,319,000 | — | -161,897,000 |
| Dec 2022 | 139,000 | -100,760,000 | -101,944,000 | 194,299,000 | 77,175,000 | — | -88,851,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,974,000
NetIncome TTM
$-161,845,000
OpCashFlow TTM
$0
Assets (Latest)
$298,420,000
Forward EPS
$-0.21
Max Pain — expiry 2026-07-17
max pain strike: $2.00 · spot: $2.57 · call oi: 7,071 · put oi: 1,827
Expected Move to 2026-07-17:
±$0.50
(19.45%) —
implied range
$2.07 –
$3.07
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $1.13B | $13.49 | — |
| WVE | Wave Life Sciences Ltd. | $1.12B | $5.83 | — |
| SPTX | Seaport Therapeutics, Inc. | $1.15B | $21.40 | — |
| XNCR | Xencor Inc | $1.12B | $15.05 | — |
| OPK | OPKO HEALTH, INC. | $1.16B | $1.53 | — |
News headlines (Yahoo Finance, 1h cache)
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?
2026-06-11 18:00 · Yahoo
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
2026-06-11 14:05 · Yahoo
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates
2026-06-04 13:14 · Yahoo
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
2026-06-03 12:00 · Yahoo
Lexicon (LXRX) Q1 2026 Earnings Transcript
2026-06-01 20:40 · Yahoo
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 12:30 · Yahoo
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)
2026-05-22 18:43 · Yahoo
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed
2026-05-13 06:13 · Yahoo
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-12 12:30 · Yahoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones
2026-05-10 04:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.